Skip to main content
VTGN
NASDAQ Life Sciences

Vistagen Therapeutics 削减20%员工以延长现金跑道至2027年

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$0.583
Mkt Cap
$24.208M
52W Low
$0.43
52W High
$5.14
Market data snapshot near publication time

summarizeSummary

Vistagen Therapeutics 宣布，自2026年3月5日起削减20%的员工，这是为了支持现金管理和其Palisade计划临床研究的一项措施。预计这一重大成本削减计划将使公司的现金跑道延长至2027年。这一行动直接解决了公司最近的10-Q文件中强调的严重财务挑战，包括对其持续经营能力的重大怀疑、净损失增加和纳斯达克退市威胁。虽然这表明公司仍然面临持续的财务困境，但这一举动是为保留资本和维持业务运营而采取的主动措施。交易者将密切关注公司临床项目的进展和任何进一步的融资努力。

在该公告发布时，VTGN的交易价格为$0.58，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2420.8万。 52周交易区间为$0.43至$5.14。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed VTGN - Latest Insights

VTGN
Apr 28, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
FDA Clears Vistagen's Refisolone for U.S. Phase 2 Trials
Sentiment: Positive
View Wiseek Article
VTGN
Apr 28, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Vistagen Receives FDA Green Light for Refisolone Phase 2 Study in Hot Flashes
Sentiment: Positive
View Wiseek Article
VTGN
Apr 02, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Vistagen Therapeutics Notifies Nasdaq of Audit Committee Non-Compliance
Sentiment: Negative
View Wiseek Article
VTGN
Mar 16, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Vistagen Therapeutics Updates Pipeline & FDA Strategy in New Corporate Presentation
Sentiment: Positive
View Wiseek Article
VTGN
Mar 11, 2026, 7:14 AM EDT
Source: Reuters
Importance Score:
8
Vistagen Therapeutics Cuts 20% of Workforce to Extend Cash Runway into 2027
Sentiment: Negative
View Wiseek Article
VTGN
Feb 20, 2026, 9:12 AM EST
Filing Type: 8-K
Importance Score:
7
Director Resigns Amidst Going Concern Doubts and Nasdaq Delisting Threat
Sentiment: Negative
View Wiseek Article
VTGN
Feb 12, 2026, 4:38 PM EST
Filing Type: 10-Q
Importance Score:
9
Vistagen Therapeutics Reports Substantial Losses, Going Concern Doubt, and New Class Action Lawsuit Amidst Nasdaq Delisting Threat
Sentiment: Negative
View Wiseek Article
VTGN
Feb 12, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
8
Vistagen Reports Increased Quarterly Loss and Higher Expenses Amidst Nasdaq Delisting Threat
Sentiment: Negative
View Wiseek Article
VTGN
Feb 06, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
9
Vistagen Therapeutics Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance
Sentiment: Negative
View Wiseek Article
VTGN
Jan 09, 2026, 5:26 PM EST
Filing Type: 8-K
Importance Score:
7
Vistagen Therapeutics Updates Clinical Pipeline and Strategy in New Corporate Presentation
Sentiment: Neutral
View Wiseek Article